Zeria Pharmaceutical Co., Ltd.
Notice Regarding Acquisition of Interests in Haupt Pharma Wülfling GmbH by Our Consolidated Subsidiary (Making It a Subsidiary)
Tillotts will acquire 100% of HPW's interests to internalize manufacturing at that site, strengthening manufacturing capacity and quality control. The transferor is Aenova; HPW is a Germany-based site. Ownership ratio before acquisition 0% → after acquisition 100%. Execution planned for 2027 or later.
Key Figures
- Acquired Ownership Ratio: 100%
- Schedule of Changes: Share transfer agreement signing date October 23, 2026 (Swiss time), Share transfer execution date January 2027 or later
- Investors / Ownership Ratio (HPW): Aenova Holding GmbH 100%, Tillotts to make HPW a 100% subsidiary
AI要約
Overview of M&A and Interest Acquisition
Zeria Pharmaceutical Co., Ltd., through its Swiss subsidiary Tillotts, will acquire all interests in Haupt Pharma Wülfling GmbH held by Aenova Holding GmbH, and internalize manufacturing at that site to expand Tillotts’ pharmaceutical manufacturing base. HPW possesses advanced expertise in development, manufacturing and packaging of solid dosage forms and handling of clinical trial supplies; leveraging its long-standing experience will strengthen the Group’s manufacturing capacity, production planning and quality management. Closing requires approval from relevant authorities, and execution is scheduled for January 2027 or later.
Impact and Future Outlook
The acquisition aligns with Tillotts’ long-term strategy and aims to enhance the Group’s corporate value over the medium to long term. By making HPW a 100% subsidiary, expansion of manufacturing capacity and improvements in quality and production efficiency are expected, establishing a structure capable of supporting future portfolio expansion. Any additional matters requiring disclosure will be announced promptly.
Zeria Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
